ID   ST486
AC   CVCL_1712
SY   ST 486
DR   CLO; CLO_0009143
DR   EFO; EFO_0002353
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1647
DR   BioSample; SAMN03471412
DR   BioSample; SAMN10988193
DR   Cell_Model_Passport; SIDM01198
DR   ChEMBL-Cells; CHEMBL3308887
DR   ChEMBL-Targets; CHEMBL2366293
DR   Cosmic; 687853
DR   Cosmic; 910906
DR   Cosmic; 931134
DR   Cosmic-CLP; 910906
DR   DepMap; ACH-000567
DR   GDSC; 910906
DR   GEO; GSM887649
DR   GEO; GSM888741
DR   GEO; GSM1670480
DR   IARC_TP53; 182
DR   IARC_TP53; 27043
DR   IGRhCellID; ST486
DR   LiGeA; CCLE_392
DR   PharmacoDB; ST486_1497_2019
DR   Wikidata; Q54955752
RX   PubMed=1325212;
RX   PubMed=2052620;
RX   PubMed=3080238;
RX   PubMed=3921823;
RX   PubMed=6243721;
RX   PubMed=6243722;
RX   PubMed=6265077;
RX   PubMed=6286763;
RX   PubMed=6328505;
RX   PubMed=7757991;
RX   PubMed=8344493;
RX   PubMed=8515068;
RX   PubMed=9473234;
RX   PubMed=9643977;
RX   PubMed=9973220;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
CC   Characteristics: EBV-negative.
CC   Doubling time: 19-20 hours (ATCC).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: MYC-IGH gene fusion (PubMed=6328505; PubMed=9643977).
CC   Sequence variation: TP53 p.Arg158His (c.473G>A) (PubMed=2052620; PubMed=8344493).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=0.3%; Native American=2.43%; East Asian, North=1.27%; East Asian, South=0%; South Asian=1.74%; European, North=54.96%; European, South=39.3% (PubMed=30894373).
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8,12
ST   D16S539: 9,12
ST   D5S818: 11,12
ST   D7S820: 7,12
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 28
RX   PubMed=1325212; DOI=10.1182/blood.V80.5.1289.1289;
RA   Benjamin D., Knobloch T.J., Dayton M.A.;
RT   "Human B-cell interleukin-10: B-cell lines derived from patients with
RT   acquired immunodeficiency syndrome and Burkitt's lymphoma
RT   constitutively secrete large quantities of interleukin-10.";
RL   Blood 80:1289-1298(1992).
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
RX   PubMed=3080238;
RA   Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.;
RT   "Expression of surface antigens during the cell cycle in different
RT   growth phases of American and African Burkitt's lymphoma cell lines.";
RL   Cancer Res. 46:1182-1188(1986).
RX   PubMed=3921823; DOI=10.1128/mcb.5.3.501;
RA   Showe L.C., Ballantine M., Nishikura K., Erikson J., Kaji H.,
RA   Croce C.M.;
RT   "Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma
RT   cell line that is translocated to a germ line alpha switch region.";
RL   Mol. Cell. Biol. 5:501-509(1985).
RX   PubMed=6243721; DOI=10.1093/jnci/64.3.465;
RA   Magrath I.T., Pizzo P.A., Whang-Peng J., Douglass E.C., Alabaster O.,
RA   Gerber P., Freeman C.B., Novikovs L.;
RT   "Characterization of lymphoma-derived cell lines: comparison of cell
RT   lines positive and negative for Epstein-Barr virus nuclear antigen. I.
RT   Physical, cytogenetic, and growth characteristics.";
RL   J. Natl. Cancer Inst. 64:465-476(1980).
RX   PubMed=6243722; DOI=10.1093/jnci/64.3.477;
RA   Magrath I.T., Freeman C.B., Pizzo P.A., Gadek J., Jaffe E.,
RA   Santaella M., Hammer C., Frank M., Reaman G., Novikovs L.;
RT   "Characterization of lymphoma-derived cell lines: comparison of cell
RT   lines positive and negative for Epstein-Barr virus nuclear antigen.
RT   II. Surface markers.";
RL   J. Natl. Cancer Inst. 64:477-483(1980).
RX   PubMed=6265077;
RA   Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E.,
RA   Sherrick D., Gray T.;
RT   "Examination of Epstein-Barr virus and C-type proviral sequences in
RT   American and African lymphomas and derivative cell lines.";
RL   Cancer Res. 41:3165-3171(1981).
RX   PubMed=6286763;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
RX   PubMed=6328505; DOI=10.1073/pnas.81.10.3170;
RA   Croce C.M., Erikson J., ar-Rushdi A., Aden D., Nishikura K.;
RT   "Translocated c-myc oncogene of Burkitt lymphoma is transcribed in
RT   plasma cells and repressed in lymphoblastoid cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:3170-3174(1984).
RX   PubMed=7757991;
RA   Bae I., Fan S., Bhatia K., Kohn K.W., Fornace A.J. Jr., O'Connor P.M.;
RT   "Relationships between G1 arrest and stability of the p53 and
RT   p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma
RT   cells.";
RL   Cancer Res. 55:2387-2393(1995).
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
RX   PubMed=8515068;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
RX   PubMed=9643977; DOI=10.1016/S0378-1119(98)00104-8;
RA   Khaira P., James C.D., Leffak M.;
RT   "Amplification of the translocated c-myc genes in three Burkitt
RT   lymphoma cell lines.";
RL   Gene 211:101-108(1998).
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G.,
RA   Magrath I.T., Bhatia K.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).